FRAMINGHAM, Mass.--(BUSINESS WIRE)--GTC Biotherapeutics, Inc. (“GTC”, NASDAQ: GTCB) and its strategic partner LFB Biotechnologies (Les Ulis, France) announced that, following discussions with the FDA, they are moving forward with their plans to file an IND for a phase I study for the transgenically derived recombinant human Factor VIIa (rhFVIIa) being developed in their joint venture. This rhFVIIa is being developed for the treatment of hemophilia patients who have developed antibodies to Factor VIII or Factor IX. GTC and LFB plan to initiate the phase I study in the second quarter of 2010.
